Introduction In the domain of oncology, immunotherapy has emerged as a pioneering methodology, harnessing the body's immune system to combat malignant tumors. There are many immunotherapeutic approaches, but Chimeric Antigen Rece..
Introduction Cytokine Release Syndrome (CRS) is an immune system overreaction triggered by therapies like immunotherapy or CAR-T cell treatment. It prompts an influx of cytokines, causing symptoms ranging from fever to potentiall..
Patients undergoing outpatient CAR T-cell therapy for cancer must be cared for by a multidisciplinary team that includes nurse coordinators, according to a poster presented at the 49th Annual Oncology Nursing Society Conference. ..
Introduction CAR T cell therapy, an innovative form of immunotherapy, has demonstrated exceptional efficacy in the treatment of specific tumors by leveraging the potency of a patient's own immune system. Recently, scientists have..
Feb 2024: China's pioneering efforts in creating breakthrough cancer therapeutics have gained traction with the introduction of chimeric antigen receptor (CAR)-engineered T-cell (CAR T) therapy for multiple myeloma, a devastatin..
Discover the magic of CAR-T treatment! Read our blog on patient selection for CAR T therapy. Are you the ideal candidate for this innovative cancer treatment? Find out and begin your personalized journey to cancer recovery. He..
ການປະຕິວັດ CAR T Cell Therapy ກໍາລັງປ່ຽນແປງສະຖານະການຂອງວິທີທີ່ພວກເຮົາຈັດການກັບມະເຮັງ, ເຮັດໃຫ້ມັນເປັນສ່ວນບຸກຄົນແລະມີອໍານາດຫຼາຍ. ການປິ່ນປົວຫລ້າສຸດນີ້ໃຊ້ຈຸລັງພູມຕ້ານທານຂອງຄົນເຈັບເອງແລະດັດແປງພັນທຸກໍາໃຫ້ເຂົາເຈົ້າເພື່ອເປົ້າຫມາຍແລະ des..
ເດືອນພຶດສະພາ 2023: Chimeric antigen receptor (CAR) ການປິ່ນປົວດ້ວຍ T-cell ແມ່ນການພັດທະນານະວັດກໍາໃນພາກສະຫນາມຂອງການປິ່ນປົວມະເຮັງສ່ວນບຸກຄົນ. ຈຸລັງ T ຂອງຄົນເຈັບເອງໄດ້ຖືກດັດແປງພັນທຸກໍາໃນລະຫວ່າງຂະບວນການຜະລິດເພື່ອສະແດງອອກ..
ເດືອນມີນາ 2023: ບົດທຳອິດຂອງບົດບັນທຶກຂອງ Sam Neill ຈະເປັນຄວາມຕົກໃຈຢ່າງໃຫຍ່ຫຼວງຕໍ່ຄົນທີ່ບໍ່ຮູ້ມາກ່ອນ. ມັນເລີ່ມເປັນເລື່ອງຕະຫລົກພໍສົມຄວນ: ເສັ້ນດ້າຍໃຫຍ່ກ່ຽວກັບລູກສາວຂອງລາວ Elena ຖືກຖາມກ່ຽວກັບພໍ່ຂອງລາວ..
ເດືອນມີນາ 2023: ສະຫຼຸບໂດຍຫຍໍ້: ຈຸດປະສົງຂອງການທົດລອງທາງດ້ານຄລີນິກນີ້ແມ່ນເພື່ອຊອກຫາວ່າຢາຕ້ານ MESO antigen receptor CAR T-cell therapy ສາມາດຖືກນໍາໃຊ້ເພື່ອປິ່ນປົວມະເຮັງຮວຍໄຂ່ epithelial ທີ່ກັບຄືນມາຫຼືຢຸດເຊົາການຕອບສະຫນອງກັບອື່ນໆ..